- Home
- CMRX vs NEWT Comparison
CMRX vs NEWT Comparison
Compare CMRX & NEWT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMRX
- NEWT
- Stock Information
- Founded
- CMRX 2000
- NEWT 1998
- Country
- CMRX United States
- NEWT United States
- Employees
- CMRX N/A
- NEWT N/A
- Industry
- CMRX Biotechnology: Pharmaceutical Preparations
- NEWT Major Banks
- Sector
- CMRX Health Care
- NEWT Finance
- Exchange
- CMRX Nasdaq
- NEWT Nasdaq
- Market Cap
- CMRX 394.1M
- NEWT 335.7M
- IPO Year
- CMRX 2013
- NEWT N/A
- Fundamental
- Price
- CMRX $8.51
- NEWT $11.99
- Analyst Decision
- CMRX Hold
- NEWT Hold
- Analyst Count
- CMRX 4
- NEWT 4
- Target Price
- CMRX $8.51
- NEWT $14.50
- AVG Volume (30 Days)
- CMRX 8.5M
- NEWT 189.4K
- Earning Date
- CMRX 03-21-2025
- NEWT 05-05-2025
- Dividend Yield
- CMRX N/A
- NEWT 6.43%
- EPS Growth
- CMRX N/A
- NEWT 4.25
- EPS
- CMRX N/A
- NEWT 1.96
- Revenue
- CMRX $212,000.00
- NEWT $338,730,000.00
- Revenue This Year
- CMRX $2,685.38
- NEWT N/A
- Revenue Next Year
- CMRX $1,050.23
- NEWT $20.67
- P/E Ratio
- CMRX N/A
- NEWT $6.05
- Revenue Growth
- CMRX N/A
- NEWT 24.93
- 52 Week Low
- CMRX $0.75
- NEWT $10.66
- 52 Week High
- CMRX $8.53
- NEWT $15.49
- Technical
- Relative Strength Index (RSI)
- CMRX 83.55
- NEWT 43.24
- Support Level
- CMRX $8.41
- NEWT $12.29
- Resistance Level
- CMRX $8.52
- NEWT $12.66
- Average True Range (ATR)
- CMRX 0.02
- NEWT 0.35
- MACD
- CMRX -0.14
- NEWT -0.01
- Stochastic Oscillator
- CMRX 72.22
- NEWT 47.58
About CMRX Chimerix Inc.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.
About NEWT NewtekOne Inc.
NewtekOne Inc is a financial holding company engaged in providing financial solutions, It has developed a financial and technology-based business model that enables itself to acquire and process its clients in a very cost-effective manner. This capability is supported in large part by NewTracker, its patented prospect management technology software, that will allow NewtekOne clients to easily interact with NewtekOne subject matter experts in the areas of Banking, Lending, Payments, Technology, Payroll, and Insurance. It offers NewtekOne's clients a single online dashboard to access all of NewtekOne's business and financial solutions. It has four reportable segments Banking, Technology, NSBF, and Payments.